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	 Noble	 metal	 nanoparticles	 were	 synthesized	 directly	 by	 pulsed	 laser	 ablation	 (Nd:YAG,
λ=1064	 nm)	 of	 gold	 and	 silver	 plates	 immersed	 in	 pure	 water.	 Concentrations	 of	 the
nanoparticles	 were	 determined	 by	 atomic	 absorption	 spectroscopy	 measurement.	 Atomic
force	microscope	 and	 transmission	 electron	microscope	 analysis	were	 used	 to	 characterize
the	 size	 and	 size	 distributions	 of	 the	 metals	 nanoparticles.	 The	 objective	 of	 this	 work	 is
studying	 the	 effects	 of	 presence	 gold	 and	 silver	 nanoparticles	 on	 the	 levels	 of	 tri‐
iodothyronine	hormone	(T3)	in	saliva	of	patients	with	chronic	renal	failure	their	thyroid	had
disorder	 (hypothyroidism).	 Also	 the	 study	 characterized	 the	 binding	 between	 the	 anti‐
T3antibody	with	its	antigen	i.e.,	T3	in	saliva	patients	in	the	presence	affixed	size	concentration
of	nanoparticles	to	improve	and	modify	a	competitive	ELISA	method.	It	is	found	that	both	gold
and	 silver	 nanoparticles	 demonstrated	 activation	 effect	 on	 the	 binding	 between	 anti‐T3
antibody	and	antigen	(T3)	in	the	saliva	of	patients	and	these	effects	increased	with	increasing
the	 concentrations	 and	 size	 for	 both	 nanoparticles	 (gold	 was	 more	 activation	 effect	 than
silver).	Optimization	of	experimental	conditions	for	the	binding	in	the	saliva	were:	40	μL	and
20	μL	of	saliva	(T3)	in	presence	both	silver	and	gold	nanoparticle,	respectively,	pH	=	7.4	of	0.2
M	phosphate	buffer	was	selected	as	the	detection	solution,	the	temperature	of	incubation	was
22	 °C	 while	 the	 incubation	 time	 were	 30	 min,	 90	 min	 for	 silver	 and	 gold	 nanoparticles,
respectively.	
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1.	Introduction	
	
Nanotechnology	 is	a	growing	field	of	study	focused	on	the	
development	 of	materials	 size	 less	 than	 100	 nm,	which	 deals	
with	synthesis	of	nanoparticles	 (NPs)	of	various	sizes,	 shapes,	
chemical	 compositions	 and	 controlled	 dispersity	 and	 their	
potential	 use	 for	 human	 benefits	 [1].	 It	 is	 applied	 to	 various	
fields	 such	 as	 physical,	 chemical,	 biological	 and	 engineering	
sciences	where	novel	techniques	are	being	developed	to	probe	
and	manipulate	single	atoms	and	molecules.	Among	all	NPs	the	
metallic	 one	 have	 applications	 in	 diverse	 areas	 such	 as	
electronics,	 cosmetics,	 coating,	 packaging	 and	 biotechnology	
[2].	NPs	can	traverse	through	the	vasculature	and	localize	any	
target	 organ,	 this	 leads	 to	 novel	 therapeutic,	 imaging	 and	
biomedical	 application	 [3].	 Ag	 nanoparticles	 (AgNPs)	 and	 Au	
nanoparticles	(AuNPs)	are	mostly	used	in	application	research	
in	nanotechnology	[4].	
In	 this	 study,	 noble	 metal	 AuNPs	 and	 AgNPs	 were	
synthesized	 by	 using	 pulsed	 laser	 ablation	 (Q‐switched,	 1064	
nm,	 Nd:YAG)	 of	 gold	 and	 silver	 metal	 plates	 immersed	 in	
distilled	 deionized	 water(DDW).	 It	 is	 Alternative‐novel,	 easy,	
fast	 and	 one‐step	 (based	 on	 Pulsed	 Laser	 Ablation	 in	 Liquids	
medium	denoted	by	PLAL)	method	for	the	preparation	of	pure	
and	stable	metal	versatile	NPs	in	a	high	ablation	rate	and	size‐
selected	 manner	 with	 a	 high	 concentration,	 long	 period	 of	
stability,	less	aggregation,	nontoxic	and	contamination	[5].	
The	 kidney	 normally	 plays	 an	 important	 role	 in	 the	
metabolism,	 degradation	 and	 excretion	 of	 several	 thyroid	
hormones.	Chronic	renal	 failure	(CRF)	affects	 thyroid	 function	
in	 many	 ways,	 including	 low	 circulating	 thyroid	 hormone	
levels,	 altered	 peripheral	 hormone	 metabolism,	 insufficient	
binding	 to	 carrier	 proteins,	 and	 possible	 reduction	 in	 tissue	
hormone	 content	 and	 altered	 iodide	 storage	 in	 the	 thyroid	
gland	 [6].	 Thus,	 patients	 with	 renal	 failure	 may	 have	 various	
abnormalities	of	thyroid	function	[7].	Tri‐iodothyronine	(T3)	is	
a	 tyrosine	 derivative	 hormone	 synthesized	 and	 stored	 in	 the	
thyroid	 gland.	 More	 than	 99%	 of	 T3in	 the	 blood	 is	 bound	
reversibly	to	plasma	proteins.	The	concentration	of	T3	is	much	
lower	 than	 that	 of	 thyroxin	 T4,	 but	 its	 metabolic	 potency	 is	
much	 greater	 [8].	 Saliva	 is	watery	 substance	 produced	 in	 the	
mouths	 of	 humans	 and	most	 other	 animals.	 Produced	 in	 and	
secreted	from	the	three	pairs	of	major	and	hundreds	of	minor	
salivary	 gland	 [9].	 Saliva	 can	 be	 collected	 with	 or	 without	
stimulation.	 Unstimulated	 whole	 saliva	 is	 the	 mixture	 of	 the	
secretions	which	enter	the	mouth	in	the	absence	of	exogenous	
gustatory,	masticatory	or	mechanical	stimulation	[10].	Interest	
in	 saliva	 as	 a	 diagnostic	 fluid	 has	 grown	 in	 recent	 years	 and	
monitoring	of	makers	in	saliva	instead	of	serum	is	found	to	be	
advantageous	 [11].	 The	enzyme‐linked	 immuno	sorbent	 assay	
(ELISA)	 is	 the	 technique	 most	 commonly	 used	 by	 molecular	
biologists	 for	 biomarker	 detection	 and	 quantification.	 ELISA	
tests	are	based	on	the	principle	of	a	solid	phase	enzyme‐linked	
immunosorbent	 assay	 using	 the	 spectroscopic	 detection	 of	 a	
colored	 reagent	 [12,13].	 The	 aims	 of	 the	 work	 are	 to	
preparation	 of	 more	 stable‐dispersed	 and	 size‐controlled	 of	
pure	 AuNPs	 and	 AgNPs	 in	 easy,	 fast	 and	 simple	method	with	
highly	 ablation	efficiency	and	studying	 the	effects	of	presence	
AuNPs	and	AgNPs	on	 the	 levels	of	T3	 in	 sera	of	patients	with	
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CRF	 whose	 their	 thyroid	 had	 hyperthyroidism	 and	 improved	
and	modified	a	competitive	ELISA	method.		
	
1.1.	Theoretical	concept	
	
The	 PLAL	 process	 is	 currently	 explored	 as	 a	 prospective	
top‐down	 (dispersion	 method)	 strategy	 of	 metals	 NPs	
preparation	 [14].	 It’s	 simple	 no	 chemistry	 is	 involved	 and	
basically	 free	 from	 limitations	 because	 it	 can	 generate	 NPs	
without	counter‐ions	or	surface‐active	substances	[15].	When	a	
high	 power	 pulsed	 laser	 beam	 irradiates	 on	 a	metal	 target	 in	
transparent	liquid,	a	local	plasma,	with	super	high	temperature	
(~6000	 K)	 and	 high	 pressure	 (~1	 GPa),	 will	 instantly	 be	
produced	on	the	solid‐liquid	interface	and	quench	quickly	after	
one	 pulse	 due	 to	 adiabatic	 expansion	 of	 the	 plasma	 and	 its	
interaction	with	surrounding	media	[5].	
The	 level	 of	 T3	 was	 determined	 by	 using	 ELISA,	 a	
competitive	 heterogeneous	 assay;	 utilize	 a	 monoclonal	
antibody	 directed	 against	 a	 distinct	 antigenic	 determinant	 on	
the	intact	biomarker	antigen	molecule.	It	is	used	for	solid	phase	
immobilization	 (on	 the	 microtiter	 wells),	 horseradish	
peroxidase	 (HRP)	 the	 most	 commonly	 used	 ELISA	 enzymes	
which	is	desired	antibody	label	due	to	it	being	the	smallest	and	
most	 stable	 [12].	 The	 application	 of	 AuNPs	 and	 AgNPs	 to	
commercially	available	T3‐competitive	ELISA	test	can	be	useful	
to	improve	and	modify	ELISA	method	[16,17].		
	
2.	Experimental	
	
2.1.	Preparation	and	characterization	of	AuNPs	and	AgNPs	
	
AuNPs	and	AgNPs	were	prepared	by	 irradiating	a	metallic	
target	plates	with	a	thickness	of	1	mm	placed	on	the	bottom	of	
quartz	 vessel	 containing	 DDW	with	 a	 pulsed	 laser	 beam.	 The	
ablation	 was	 performed	 with	 the	 1064	 nm	 of	 Nd:YAG	 laser	
(HUAFEI)	operating	at	10	Hz	repetition	rate,	with	a	pulse	width	
of	10	ns	at	energy	set	 in	500,	600,	700	mJ/pulse	 for	gold	and	
500,	600,	750	mJ/Pulse	for	silver	with	a	positive	lens	having	a	
focal	 length	 of	 9	 cm.	 The	 spot	 size	 was	 about	 1.5	 mm	 in	
diameter	 and	 the	 liquid	 thickness	 was	 changed	 in	 the	 range	
from	2‐14	mm	to	increase	the	shock	wave	and	it’s	adjusted	by	
using	 different	 dimension	 of	 cells.	 The	 number	 of	 laser	 shots	
applied	 for	 the	 metal	 target	 was	 400	 pulses.	 Atomic	 force	
microscope	 (AFM)	 (Model	 AA3000,	 Angstrom	 Advance	 Inc.,	
USA)	 and	 transmission	 electron	 microscope	 (TEM)	 (CM10‐
PW6020,	Philips,	Germany)	were	used	to	examine	the	size	and	
size	distributions	of	the	metals	nanoparticles	[18].	
Absorbance	spectra	of	the	NPs	solution	were	measured	by	
UV‐Vis	 double	 beam	 spectrophotometer	 (Cary‐100	 Conc,	
Australia).	 The	 NPs	 concentration	 was	 also	 characterized	 by	
Atomic	Absorption	Spectroscopy	(AA‐680,	Shimadzu‐Japan).	
	
2.2.	Saliva	samples	collection	
	
Before	 collecting	 saliva	 the	 CRF	 patients	 (From	 ALHYAT	
center	 for	 kidney	 diseases	 in	 Al‐Karama	 Hospital,	 Baghdad,	
Iraq)	were	asked	not	to	eat	or	drink	for	at	 least	an	hour.	After	
that	 they	 rinsed	 their	 mouths	 several	 times	 by	 water,	 then	
waiting	for	1‐2	min.	(for	water	clearance).	Unstimulated	saliva	
was	 collected	 in	 sterilized	 clear	 containers.	 The	 saliva	 was	
centrifuged	at	1500	g	for	10	min.	and	then	kept	frozen	at	‐20	°C	
until	the	time	of	assay	[19,20].	
	
2.3.	Detection	affect’s	type	of	AuNPs	and	AgNPs	on	T3‐
binding	
	
ELISA	 kits	 for	 T3‐hormone	 were	 purchased	 from	 human	
(Wiesbaden,	 Germany),	 it	 is	 based	 on	 the	 principle	 of	
competitive	binding	between	T3	 in	 the	 test	specimen	and	T3‐
peroxidase	conjugate	 for	a	 limited	number	of	binding	sites	on	
the	 anti‐T3	 (sheep)	 coated	 well.	 Thus	 the	 amount	 of	 T3‐
peroxidase	 conjugate	 bound	 to	 the	 well	 is	 inversely	
proportional	to	 the	concentration	of	T3	in	 the	specimen.	After	
incubation,	unbound	enzyme	conjugate	is	removed	by	washing.	
Tetramethylbenzidin	(TMB)/substrate	solution	is	added,	and	a	
blue	color	develops.	The	 intensity	of	this	color,	which	changes	
to	yellow	after	stopping	the	reaction,	 is	 inversely	proportional	
to	the	amount	of	T3	in	the	specimen.	The	general	procedure	is	
summarized	 as	 follow:	 Standard	 solutions	 containing	 0.0,	 0.5,	
1.0,	2.5,	5.0	and	7.5	ng/mL	of	T3‐hormones	were	used	(50	µL	
for	each	well)	to	plotting	the	standard	curve.	In	other	strips	50	
µL	of	saliva	specimen	(from	CRF	patients),	10	µL	of	AuNPs	(15	
ppm)	and	AgNPs	 (20	ppm)	were	added	 to	 calculate	 the	T3	 in	
the	presence	of	NPs	or	10µL	of	DDW	to	calculate	the	T3	without	
presence	 of	 NPs.	 100	 µL	 of	 working	 conjugate	 solution	
(Enzyme‐antigen	 conjugate	 and	 conjugate	 buffer	 1:10)	 was	
added,	 rock	 gently	 and	 cover	 the	 strips	 with	 adhesive	 strip,	
then	 incubate	 60	 min	 at	 20‐25	 °C,	 the	 wells	 were	 washed	 3	
times	 with	 300	 µL	 (Tris	 buffered	 saline),	 working	 wash	
solution	(diluted	2mL	to	100	mL	with	fresh,	deionized	water),	
then	 100	 µL	 of	 the	 substrate	 reagent	 solution	 was	 added	
without	shaking	the	plate	after	addition,	incubate	for	15	min	at	
20‐25	°C	and	stop	solution	was	added	(50	µL),	mixed	carefully	
and	measure	the	absorbance	at	450	nm	as	soon	as	possible	or	
within	30	min	after	 terminating	of	 reaction,	using	a	 reference	
wavelength	of	630‐690	nm	(if	available).		
The	activation	percentages	of	binding	between	antigen	and	
antibody	were	 calculated	 by	 comparing	 the	 T3	 concentration	
with	 and	 without	 the	 NPs	 colloids	 and	 under	 the	 same	
conditions,	according	to	the	equation:	
	
%Activation=	100	x	[T3	in	the	presence	of	NPs	/	T3	in	the	
absence	of	NPs]‐100	 	 	 	 (1)	
	
2.4.	Characterization	the	T3‐binding	in	the	presence	of	NPs	
	
2.4.1.	Determination	the	optimum	concentrations	of	NPs	on	
T3‐binding	
	
A	 stock	 solution	 (15	 ppm)	 concentration	 of	 AuNPs	 (700	
mJ/Pulse)	 and	 (20	 ppm)	 concentration	 of	 AgNPs	 (750	
mJ/Pulse)	and	then	the	following	concentrations	12.0,	9.0,	6.0,	
3.0,	 1.0,	 0.5	ppm	and	16.0,	 12.0,	 8.0,	 4.0,	 2.0,	 1.0,	 0.5	ppm	 for	
each	AuNPs	 and	AgNPs,	 respectively,	were	prepared	 by	 serial	
dilution	from	the	stock	solution	with	DDW.	
	
2.4.2.	Determination	the	optimum	Antigen	(Saliva)	
concentrations	onT3‐	binding	
	
A	 different	 volume	 of	 Antigen	 (Saliva	 T3‐Antigen)	 were	
used	 50,	 40,	 30,	 20,	 10,	 5	 µL	 and	 the	 volume	 of	 the	mixture	
were	 completed	 to	 50	 µL	 with	 DDW;	 other	 optimized	
conditions	were	used,	as	followed	previously.		
	
2.4.3.	Determination	the	optimum	pH	
	
A	 different	 pH	 value	 of	 phosphate	 buffer	 (0.2	 M)	 were	
tested	 (pH	 =	 6.8,	 7.0,	 7.2,	 7.4,	 7.6,	 7.8)	 and	 other	 optimized	
conditions	were	used.	
	
2.4.4.	Determination	the	optimum	incubation	temperature	
	
Incubation	 temperature	 was	 affected	 the	 performance	 of	
ELISA	 condition,	 therefore,	 various	 temperature	5,	 12,	22,	 37,	
45	 °C	 of	 antigen‐antibody	 reaction	were	 evaluated,	 and	 other	
optimized	conditions	were	used.	
	
2.4.5.	Determination	the	optimum	incubation	time	
	
Various	 incubation	 time	 15,	 30,	 60,	 90,	 120	 min	 of	 antigen‐
antibody	 reaction	 were	 evaluated,	 and	 other	 optimized	
conditions	were	used.	
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Table	1.The	concentration	by	AAS	and	the	average	diameter	by	AFM	for	AuNPs	(A,	B,	C)	and	AgNPs	(D,	E,	F).	
Concentration	(ppm)		 Average	diameter	(nm)		 Energy	(mJ)	 Concentration	(ppm) Average	diameter	(nm)		 Energy	(mJ)	
0.59		 75.72		 D)Ag‐500	 9.74	 58.14	 A)Au‐500	
6.55		 75.47		 E)Ag‐600	 11.98	 83.28	 B)Au‐600	
20.01		 61.87		 F)Ag‐750	 15.00	 52.03	 C)Au‐700	
	
	
2.4.6.	Determination	the	optimum	particle	size	
	
A	three	different	particle	size	of	AuNPs	(Average	diameter:	
58.14,	 83.28,	 53.03	 nm)	 by	 using	 different	 laser	 energy	 500,	
600,	700	mJ/Pulse,	respectively,	and	AgNPs	(Average	diameter:	
75.72,	 75.47,	 61.87	 nm)	 by	 using	 different	 laser	 energy	 500,	
600,	 750	 mJ/Pulse,	 respectively.	 From	 the	 solutions	 for	 the	
three	particles	size	synthesized,	AuNPs	(5	ppm)	and	AgNPs	(0.5	
ppm)	were	prepared	by	diluting	with	DDW.	
	
3.	Results	and	discussion	
	
The	preparation	of	pure	noble	metals	of	AuNPs	and	AgNPs,	
which	 addressed	 in	 this	 research,	 have	 significant	 biological	
and	 chemical	 effects	 [19,21‐28],	 and	 investigation	 of	 the	
biomedical	 applications	 of	 these	 NPs	 to	 the	 commercially	
available	ELISA	test.	
	
3.1.	Characterization	of	the	NPs	
	
Figure	1	and	2	show	the	Surface	Plasmon	Resonance	(SPR)	
absorption	spectrum	of	colloidal	solutions	of	AuNPs	and	AgNPs,	
respectively.	In	Figure	1,	the	pulse	energy	at	the	target	surface	
were	 varied	 from	 A‐500,	 B‐600,	 C‐700	 mJ/Pulse	 for	 AuNPs,	
which	 show	 the	 absorbance	 peaks	 with	 broad	 band	 around	
525nm,	with	the	peak	position	remaining	practically	constant,	
that	indicates	the	production	of	AuNPs	[29,30].	We	observed	a	
faint	pink	coloration	of	the	solution	after	several	pulses	of	 the	
experiment,	 as	 shown	 in	 optical	 picture.	 In	 the	 absorption	
spectra	of	the	solutions,	the	surface	plasmon	related	peak	could	
be	clearly	distinguished.	These	peaks	were	around	520‐530	nm	
and	 its	 intensity	 increased	 with	 increasing	 the	 pulse	 energy	
from	 A‐500	 mJ/Pulse	 to	 B‐600	 mJ/Pulse	 to	 700	 mJ/Pulse,	
which	 found	 to	 be	 dependent	 upon	 the	 laser	 shots	 [5].	 These	
peaks	 were	 consistent	 with	 the	 presence	 of	 small	 20‐90	 nm	
particles	in	the	colloid,	which	also	confirmed	by	AFM	and	TEM,	
as	compared	to	other	reference,	shows	the	presence	of	small	3‐
30	nm	particles	in	the	colloid	[31].	
	
	
	
Figure	1.	UV‐Vis	 spectrum	 and	 optical	 picture	 of	 AuNPs	 obtained	 by	 laser	
ablation	 of	 metal	 plates	 immersed	 in	 DDW	 with	 laser	 energy	 of	 (A‐500	
mJ/Pulse,	 B‐600	mJ/Pulse,	 C‐700	mJ/Pulse)	 laser	 shots	 of	 400	 pulses	 and	
wave	length	is	1064	nm	of	Nd:YAG.	
	
Figure	 2	 shows	 the	 absorbance	 peaks	 that	 occurred	 at	
around	400	nm	is	the	characteristic	of	AgNPs	[32].	The	pulses	
energy	at	the	target	surface	were	varied	from	E‐500,	F‐600,	G‐
750	mJ/Pulse,	which	show	the	increasing	of	height	and	width	of	
peaks	were	found	to	be	dependent	upon	the	laser	shots	and	its	
intensity	 increased	 with	 increasing	 the	 pulse	 energy.	 AgNPs	
was	faint	yellow	in	color	as	shown	in	optical	picture.		
Table	1	shows	the	concentrations	of	AuNPs	and	AgNPs,	for	
each	 pulse	 energy	 in	 liquid	 by	 using	 atomic	 absorption	
spectrophotometer,	 as	 a	 function	 of	 gold	 and	 silver	 standard	
concentration	samples	to	make	the	calibration	curve.	This	table	
also	 shows	 the	average	diameter	 (nm)	 for	each	solution	used.	
The	results	showed	that	the	concentration	of	NPs	increase	with	
increasing	 the	 pulses	 energy,	 while	 we	 see	 the	 average	
diameter,	in	general,	decreased.		
	
	
	
Figure	2.	UV‐Vis	 spectrum	 and	 optical	 picture	 of	 AgNPs	 obtained	 by	 laser	
ablation	 of	 metal	 plates	 immersed	 in	 DDW	 with	 laser	 energy	 of	 (D‐500	
mJ/Pulse,	 E‐600	 mJ/Pulse,	 F‐750	mJ/Pulse)	 laser	 shots	 of	 400	 pulses	 and	
wave	length	is	1064	nm	of	Nd:YAG.	
	
Figure	 3	 and	 4	 show	 the	 AFM	 images	 and	 the	
corresponding	 size	 distribution	 of	 AuNPs	 and	 AgNPs,	
respectively,	 by	 laser	 ablation	 of	 metal	 immersed	 in	 DDW	 at	
400	 pulses	 with	 different	 pulse	 energy.	 The	 origin	 of	 the	
surface	 morphology	 of	 the	 irregularly	 shaped	 particles	 sizes	
and	 the	 size	 distribution	 broaden	 can	 be	 explained	 by	
absorption	with	defects	and	thermally	induced	pressure	pulses	
which	cause	cracking	[33].	
Figure	 5A	 and	 B	 shows	 the	 TEM	 images	 for	 AuNPs	 (700	
mJ/Pulse)	 and	 AgNPs	 (750	 mJ/Pulse),	 respectively.	 The	 NPs	
thus	produced	were	 calculated	 to	have	 the	average	diameters	
range	of	20‐60	nm	and	40‐80	nm,	respectively.	
	
3.2.	Optimization	of	the	assay	condition	
	
The	effects	of	presence	AuNPs	and	AgNPs	on	 the	 levels	of	
T3in	 saliva	 of	 patients	 with	 CRF	 whose	 their	 thyroid	 had	
disorder	 (hypothyroidism)	 showed	 activation	 effect	 (22.1%	
and	 0.66	 %),	 respectively,	 by	 using	 the	 same	 kit	 conditions	
mentioned	in	experimental	work	(step	2)	with	adding	10	µL	of	
NPs.	
The	interaction	between	proteins	and	AuNPs	depends	upon	
three	separate	but	dependent	phenomena:		
a) Ionic	 attraction	 between	 the	 negatively	 charged	
gold	and	the	positively	charged	proteins;		
b) Hydrophobic	 attraction	 between	 the	 antibody	
and	the	gold	surface;		
c) Dative	 binding	 between	 the	 gold	 conducting	
electrons	and	sulfur	atoms	which	may	occur	with	
amino	acids	of	the	proteins	[12].		
The	 AgNPs	 having	 negative	 surface	 charge	 and	 can	
demonstrate	 a	 highly	 dispersed	 state	 without	 aggregation	
because	of	the	electrostatic	repulsion	between	the	AgNPs.		
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Figure	 3.	 AFM	 images	 and	 size	 distributions	 of	 AuNPs,	 obtained	 by	 laser	
ablation	 of	 metal	 plats	 immersed	 in	 DDW	 with	 laser	 energy	 of	 (A‐500	
mJ/Pulse,	 B‐600	mJ/Pulse,	 C‐700	mJ/Pulse)	 laser	 shots	 of	 400	 pulses	 and	
wave	length	is	1064	nm	of	Nd:YAG.	
	
However,	 the	 repulsive	 forces	 are	 likely	 to	 exceed	 the	
Vander	Waals	attractive	 forces	 leading	to	coalescence	[5].	The	
conjugation	 process	 is,	 therefore,	 influenced	 greatly	 by	
different	 conditions.	 In	 studying	 the	 effect	 of	 different	
concentrations	 of	 AuNPs	 (700	 mJ/Pulse)	 and	 AgNPs	 (750	
mJ/Pulse),	which	 shown	 in	 Figure	 6A	 and	 B,	 respectively,	we	
see,	the	highest	assay	of	activation	to	binding	T3	was	achieved	
when	 the	AuNPs	 concentration	 at	 6	ppm,	while	 its	 8	ppm	 for	
AgNPs,	 therefore	 these	 concentrations	 were	 used	 in	 other	
experiments	latter.		
Figure	7A	and	B	shows	the	results	recorded	when	different	
dilutions	 of	 the	 saliva	 “Antigen”	 were	 used	 in	 the	 assay.	 The	
best	 dilution,	 which	 made	 the	 best	 activation	 were	 (20	 µL	
serum	“Antigen”	+	30	µL	DDW)	and	(40	µL	serum	“Antigen”	+	
10	µL	DDW),	respectively.	
The	 conjugation	 process	 is	 influenced	 greatly	 by	 the	 pH	
which	 determines	 the	 charges	 and	 stability	 of	 the	 protein	
ensuring	 the	 best	 NPs	 surface	 coverage	 while	 preserving	
protein	 biofunctionality,	 therefore,	 different	 pH	 values	 were	
tested	 to	 conjugated	 the	 AuNPs	 and	 AgNPs	 with	 antibody‐
antigen	binding	giving	the	results	illustrated	in	Figure	8a	and	b,	
respectively.	As	can	be	seen,	 the	highest	assay	detection	were	
achieved	 when	 the	 pH	 were	 7.4	 for	 both	 NPs,	 this	 pH	 is,	
therefore,	the	optimum	pH	for	conjugation.	
	
	
	
	
Figure	 4. AFM	 images	 and	 size	 distributions	 of	 AgNPs,	 obtained	 by	 laser	
ablation	 of	 metal	 plats	 immersed	 in	 DDW	 with	 laser	 energy	 of	 (D‐500	
mJ/Pulse,	 E‐600	 mJ/Pulse,	 F‐750	mJ/Pulse)	 laser	 shots	 of	 400	 pulses	 and	
wave	length	is	1064	nm	of	Nd:YAG.	
	
	
	
Figure	 5. TEM	 images	 of	 (A)	 AuNPs	 (700	mJ/Pulse)	 and	 (B)	 AgNPs	 (750	
mJ/Pulse),	obtained	by	laser	ablation	of	metal	plats	 immersed	in	DDW	with	
laser	shots	of	400	pulses	and	wave	length	is	1064	nm	of	Nd:YAG.	
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(A)	
	
(B)	
	
Figure	 6.	 Optimization	 of	 the	 concentration	 of	 (A)	 AuNps	 (700	mJ/Pulse)	
and	(B)	AgNPs	(750	mJ/Pulse)	to	be	used	in	the	ELISA	test.	Other	condition:	
50	µL	saliva	specimen	(CRF);	10	µL	of	NPs	(0.5‐15.0	ppm)	or	DDW;	100	µL	
working	conjugate	solution;	incubation	time	1h	at	20‐25	°C;	100	µL	substrate	
reagent	solution;	incubation	time	15	min	at	20‐25	°C;	50	µL	stop	solution.	
	
	
	
(A)	
	
(B)	
	
Figure	7.	Optimization	of	the	saliva	volume	of	(A)	AuNps	(700	mJ/Pulse)	and	
(B)	AgNPs	(750	mJ/Pulse)	to	be	used	in	the	ELISA	test.	Other	condition:	5‐50	
µL	saliva	specimen	(CRF);	10	µL	of	NPs	(6	ppm	AuNPs	and	8	ppm	AgNPs)	or	
DDW;	100	µL	working	 conjugate	 solution;	 incubation	 time	1	h	 at	20‐25	 °C;	
100	µL	substrate	reagent	solution;	incubation	time	15	min	at	20‐25	°C;	50	µL	
stop	solution.	
	
	
	
	
(A)	
	
(B)	
	
Figure	8.	pH	Optimization	of	(A)	AuNps	(700	mJ/Pulse)	and	(B)	AgNPs	(750	
mJ/Pulse)	to	be	used	in	the	ELISA	test.	Other	condition:	(20	µL	+	30	µL	DDW	
to	(A)	and	40	µL	+	10	µL	DDW	to	(B))	saliva	specimen	(CRF);	10	µL	of	NPs	(6	
ppm	AuNPs	and	8	ppm	AgNPs)	or	DDW;	100	µL	working	conjugate	solution;	
incubation	time	1h	at	20‐25	°C;	100	µL	substrate	reagent	solution;	incubation	
time	15	min	at	20‐25	°C;	50	µL	stop	solution.	
	
	
Figure	9A	and	B	shows	the	effect	of	incubation	temperature	
on	the	assay	of	ELISA	test	in	the	presence	of	AuNPs	and	AgNPs,	
respectively,	 with	 the	 increasing	 the	 incubation	 temperature,	
the	peak	increased	and	reached	a	maximum	value	at	22	°C	for	
both	of	them	and	then	decreased,	higher	than	30	°C	resulted	in	
further	decrease	of	the	response,	which	was	possible	due	to	the	
change	 in	 architecture	 of	 HRP	 or	 antigen/antibody	 complex	
conjugated	with	NPs	and	denaturation	of	the	immobilized	HRP	
[33].		
At	 the	 incubation	 temperature	 of	 22	 °C,	 the	 response	
obtained	 increased	 with	 an	 increasing	 incubation	 time	 and	
reached	 a	maximum	 at	 90	min	 and	 30	min,	 respectively,	 and	
then	decreased	(Figure	10A	and	B).		
The	effect	of	different	particle	size	of	ANPs	and	AgNPs	were	
shown	 in	 Figure	 11A	 and	 B,	 respectively.	 As	 can	 be	 seen	 in	
Figure	11A,	 the	particle	 size	was	not	 dependent	 to	 increasing	
the	 average	 diameter	 (nm)	 as	 shown.	 The	 percentages	 of	
activation	 were	 2.91%	 in	 52.03	 nm	 and	 it’s	 increased	 to	
10.46%	 in	 58.14	 nm,	 and	 11.63%	 in	 83.28	 nm.	 Figure	 11B	
showed	that	the	percentages	of	activation	were	increased,	also	
with	 increasing	 the	 particle	 size	 from	 2.67%	 in	 61.87	 nm,	 to	
5.23%	in	75.47	nm	to	5.23%	in75.72	nm.	Other	result	showed	
that	smaller	particles	would	greatly	speed	up	the	binding	when	
it’s	 used	 the	 polystyrene	 NPs	 with	 europium	 chelate	 as	
fluorescent	reporters	in	an	immunoassay	for	atrazine	[34].	This	
phenomenon	 needs	 to	 be	 further	 studied	 to	 determine	 the	
optimal	 particle	 size	 for	 binding	 the	 antibody/antigen	 and	
subsequently	for	other	molecules	of	interest.	
	
4.	Conclusion	
	
In	 this	 work,	 we	 have	 presented	 easy	 method	 for	 the	
preparation	 of	 AuNPs	 and	 AgNPs	 with	 well‐defined	 size	 and	
shape.		
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(A)	
	
(B)	
	
Figure	 9.	 Optimization	 of	 the	 incubation	 temperature	 of	 (A)	 AuNps	 (700	
mJ/Pulse)	and	(B)	AgNPs	(750	mJ/Pulse)	to	be	used	in	the	ELISA	test.	Other	
condition:	(20	µL	+	30	µl	DDW	to	(A)	and	40	µL	+	10	µL	DDW	to	(B))	saliva	
specimen	(CRF);	10	µL	of	NPs	(6	ppm	AuNPs	and	8	ppm	AgNPs)	or	DDW;	100	
µL	working	conjugate	solution;	incubation	time	1	h	at	5,	12,	22,	37,	45	°C;	100	
µL	substrate	reagent	solution;	incubation	time	15	min	at	20‐25	°C;	50	µL	stop	
solution.	
	
	
(A)	
	
(B)	
	
Figure	10.	Optimization	of	the	incubation	time	of	(A)	AuNps	(700	mJ/Pulse)	
and	(B)	AgNPs	(750	mJ/Pulse)	to	be	used	in	the	ELISA	test.	Other	condition:	
(20	µL	+	30	µL	DDW	to	(A)	and	40	µL	+	10	µL	DDW	to	(B))	saliva	specimen	
(CRF);	 10	 µL	 of	 NPs	 (6	 ppm	 AuNPs	 and	 8	 ppm	 AgNPs)	 or	 DDW;100	 µL	
working	 conjugate	 solution;	 incubation	 time	 15,30,60,90,120	min	 at	 22	 °C;	
100	µL	substrate	reagent	solution;	incubation	time15	min	at	22	°C;50	µL	stop	
solution.	
	
(A)	
	
(B)	
	
Figure	11.	The	effect	of	different	particle	size	of	(A)	AuNps	(1‐700	mJ/Pulse;	
2‐500	 mJ/Pulse;	 3‐600	 mJ/Pulse)	 and	 (B)	 AgNPs	 (1‐750	 mJ/Pulse;	 2‐600	
mJ/Pulse;	3‐500	mJ/Pulse)	 on	 the	binding	T3	 to	be	 used	 in	 the	ELISA	 test.	
Other	condition:	 50	µL	 saliva	 specimen	 (CRF);	 10	µL	 of	NPs	 (5	ppm	 for	 all	
AuNPs	 and	 0.5	 ppm	 for	 all	 AgNPs)	 or	 DDW;	 100	 µL	 working	 conjugate	
solution;	incubation	time	1h	at	20‐25	°C;	100	µL	substrate	reagent	solution;	
incubation	time	15	min	at	20‐25	°C;	50	µL	stop	solution.	
	
	
Optical	 measurements	 of	 colloidal	 NPs	 exhibit	 single,	
maximum	optical	extinction	at	around	525	nm	and	400	nm	for	
surface	Plasmon	resonance	of	AuNPs	and	AgNPs,	respectively.	
The	results	showed	that	the	concentration	of	NPs	increase	with	
increasing	 the	 pulses	 energy,	 while	 the	 average	 diameter,	 in	
general,	decreased.	
Under	optimum	conditions,	 the	AuNPs	and	AgNPs	showed	
an	 activation	 effect	 on	 the	 binding	 between	 anti‐T3	 Antibody	
and	antigen‐T3	 in	the	saliva	of	patients.	We	hypothesized	that	
NPs	 of	 Au	 and	 Ag	 interact	 with	 functional	 groups	 of	 anti‐T3	
antibody,	 resulting	 in	 protein	 denaturation	 and	 so	 NPs	 of	 Au	
and	 Ag	 activated	 the	 binding	 between	 antibody	 and	 antigen.	
Specifically,	we	were	able	to	demonstrate	that	the	particle	size	
decreases	 the	 time	 required	 for	 binding	 when	 AgNPs	 used,	
while	its	increased	the	time	when	AuNPs	used.	We	can	suggest	
that	 the	 use	 of	 larger	 particles	 would	 greatly	 speed	 up	 the	
reaction	 for	 both	 NPs.	 To	 the	 best	 of	 our	 knowledge,	 the	
present	work	 is	 the	 first	 study	 that	 demonstrate	 the	 effect	 of	
AuNPs	 and	 AgNPs	 colloids	 on	 this	 binding,	 therefore,	 a	more	
accurate	analytical	procedure	should	be	developed	in	order	to	
avoid	 mistake,	 in	 order	 to	 used	 the	 AuNPs	 and	 AgNPs	 in	
biomedical	applications	such	as	the	treatment	and	follow	up	by	
adjustment	the	levels	of	T3‐hormones	of	patients	suffered	from	
thyroid	disorder.	
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